A5054895333- Cardiac Arrhythmias and Treatments
- Cardiac pacing and defibrillation studies
- Cardiac electrophysiology and arrhythmias
- Atrial Fibrillation Management and Outcomes
- Cardiac Imaging and Diagnostics
- Cardiovascular Function and Risk Factors
- Cardiac Valve Diseases and Treatments
- Cardiomyopathy and Myosin Studies
- Cardiovascular Effects of Exercise
- Cardiac, Anesthesia and Surgical Outcomes
- Health Systems, Economic Evaluations, Quality of Life
- Heart Rate Variability and Autonomic Control
- Acute Myocardial Infarction Research
- Cardiovascular Disease and Adiposity
- Blood Pressure and Hypertension Studies
- COVID-19 Clinical Research Studies
- Congenital Heart Disease Studies
- Cardiovascular Syncope and Autonomic Disorders
- Lipoproteins and Cardiovascular Health
- Heart Failure Treatment and Management
- Pulmonary Hypertension Research and Treatments
- Cardiac Arrest and Resuscitation
- Venous Thromboembolism Diagnosis and Management
- Coronary Interventions and Diagnostics
- ECG Monitoring and Analysis
University of California, San Francisco
2023-2025
Ochsner Medical Center
2015-2024
Ochsner Health System
2011-2024
University of New Orleans
2015-2023
Stroke Association
2021-2023
Palo Alto University
2023
Stanford University
2023
Academy of Medicine
2022
The University of Queensland
2013-2021
Universidade Federal de Santa Maria
2018
Despite the high rate of sudden death after myocardial infarction among patients with a low ejection fraction, implantable cardioverter–defibrillators are contraindicated until 40 to 90 days infarction. Whether wearable cardioverter–defibrillator would reduce incidence during this high-risk period is unclear.
The subcutaneous (S) implantable cardioverter-defibrillator (ICD) is safe and effective for sudden cardiac death prevention. However, patients in previous S-ICD studies had fewer comorbidities, less left ventricular dysfunction, received more inappropriate shocks (IAS) than typical transvenous ICD trials. UNTOUCHED trial (Understanding Outcomes With the Primary Prevention Patients Low Ejection Fraction) was designed to evaluate IAS rate a typical, contemporary patient population implanted...
Abstract
Abstract Background Vest Prevention of Early Sudden Death Trial did not demonstrate a significant reduction in arrhythmic death with the wearable cardioverter‐defibrillator (WCD), but compliance device may have substantially affected results. ThePletcher influence WCD on outcomes has yet been fully evaluated. Methods Using linear and pooled logistic models, we performed as‐treated analyses omitting person‐time hospital adjusted for correlates compliance. To assess impact early stopping WCD,...
The interval between the T-wave's peak and end (Tpe), an electrocardiographic (ECG) index of ventricular repolarization, has been proposed as indicator arrhythmic risk. We aimed to clarify clinical usefulness Tpe for risk stratification. evaluated 327 patients with left ejection fraction (LVEF) ≤35% (75% male, LVEF 23 ± 7%). All had implanted implantable cardioverter-defibrillator (ICD). Clinical data ECGs were analysed at baseline. Prospective follow-up endpoints appropriate ICD therapy...
To determine whether QRS duration predicts sudden cardiac death (SCD) in patients with left ventricular hypertrophy and treated hypertension.Over 4.8 +/- 0.9 years follow-up of 9193 hypertensive electrocardiographic evidence LVH who were atenolol- or losartan-based regimens, 178 (1.9%) suffered SCD. In multivariable analysis including randomized treatment, changing blood pressure over time, baseline differences between without SCD, was independently predictive SCD (HR per 10 ms increase =...
Several published investigations demonstrated that a longer T-peak to T-end interval (Tpe) implies increased risk for ventricular tachyarrhythmia (VT/VF) and mortality. Tpe has been measured using diverse methods. We aimed determine the optimal measurement method screening purposes.We evaluated 305 patients with LVEF ≤ 35% an implantable cardioverter-defibrillator implanted primary prevention. was seven different methods described in literature, including six manual automated algorithm...
Background Oral anticoagulation reduces stroke and disability in atrial fibrillation (AF) but is underused. We evaluated the effects of a novel patient-clinician shared decision-making (SDM) tool reducing oral patient's decisional conflict as compared with usual care. Methods Results designed new digital decision aid multicenter, randomized, comparative effectiveness trial, ENHANCE-AF (Engaging Patients to Help Achieve Increased Patient Choice Engagement for AF Stroke Prevention). The...
Revascularization aims to improve myocardial perfusion. However, changes in regional artery-specific quantitative perfusion after revascularization have not been systematically investigated. It is unclear whether thresholds for coronary flow capacity (CFC) and/or relative predict improved stress revascularization. We sought determine the impact of based on predefined, artery-specific, severity size CFC defects. Fifty patients underwent PET imaging before and then prospectively within 90 days...
Background: The association of atrial fibrillation (AF) with cancer and types is inconclusive. Similarly, data regarding the AF different therapies are controversial. Objectives: To study subtypes therapies. Methods: We studied all patients aged 18–89 years who presented to Feist Weiller Cancer Center, or without a diagnosis cancer, between January 2011 February 2016. Electronic health records were systematically queried for baseline demographics ICD-9 ICD-10 codes specific co-morbidities....